STOCK TITAN

TRex Bio: Johnson & Johnson unit reports 5.3% stake

Both reporting entities are listed with shared voting and dispositive power over the position; Johnson & Johnson may be deemed its indirect beneficial owner.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

TRex Bio, Inc. reported that Johnson & Johnson Innovation-JJDC, Inc. directly beneficially owns 1,475,302 common shares, equal to 5.3% of the class. Johnson & Johnson may be deemed to indirectly beneficially own the same securities; both reporting persons reported shared voting and dispositive power. The percentage is based on 27,577,535 shares outstanding following the issuer’s initial public offering closing on October 13, 2026.

Beneficially owned common shares 1,475,302 shares Directly beneficially owned by Johnson & Johnson Innovation-JJDC, Inc.
Percent of class 5.3% Based on shares outstanding following the initial public offering closing
Common shares outstanding 27,577,535 shares Following the initial public offering closing on October 13, 2026
beneficially owned regulatory
"Amount beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Voting Power regulatory
"Shared Voting Power 1,475,302.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Power regulatory
"Shared Dispositive Power 1,475,302.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TRXB shares does Johnson & Johnson Innovation-JJDC own?

Johnson & Johnson Innovation-JJDC, Inc. directly beneficially owns 1,475,302 TRex Bio common shares; Johnson & Johnson may be deemed to indirectly beneficially own those securities.

What percentage of TRXB is reported as beneficially owned?

The reported beneficial ownership is 5.3% of TRex Bio’s common stock, based on 27,577,535 shares outstanding following the initial public offering closing on October 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates





89531N100

(CUSIP Number)
10/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Johnson & Johnson Innovation - JJDC, Inc.
Signature:/s/ Jill McManus
Name/Title:Jill McManus/Assistant Treasurer
Date:10/15/2026
JOHNSON & JOHNSON
Signature:/s/ Marc Larkins
Name/Title:Marc Larkins/Secretary
Date:10/15/2026
Exhibit Information

Joint Filing Agreement

Keep reading